HRP20180067T1 - Inhibitori histon demetilaze - Google Patents

Inhibitori histon demetilaze Download PDF

Info

Publication number
HRP20180067T1
HRP20180067T1 HRP20180067TT HRP20180067T HRP20180067T1 HR P20180067 T1 HRP20180067 T1 HR P20180067T1 HR P20180067T T HRP20180067T T HR P20180067TT HR P20180067 T HRP20180067 T HR P20180067T HR P20180067 T1 HRP20180067 T1 HR P20180067T1
Authority
HR
Croatia
Prior art keywords
pharmaceutically acceptable
compound
acceptable salt
salt according
image
Prior art date
Application number
HRP20180067TT
Other languages
English (en)
Croatian (hr)
Inventor
Toufike Kanouni
Jeffrey Alan Stafford
James Marvin Veal
Michael Brennan Wallace
Original Assignee
Celgene Quanticel Research, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Research, Inc. filed Critical Celgene Quanticel Research, Inc.
Publication of HRP20180067T1 publication Critical patent/HRP20180067T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Enzymes And Modification Thereof (AREA)
HRP20180067TT 2012-12-19 2013-12-19 Inhibitori histon demetilaze HRP20180067T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261739521P 2012-12-19 2012-12-19
US201361792930P 2013-03-15 2013-03-15
EP13866465.1A EP2934145B1 (en) 2012-12-19 2013-12-19 Histone demethylase inhibitors
PCT/US2013/076666 WO2014100463A1 (en) 2012-12-19 2013-12-19 Histone demethylase inhibitors

Publications (1)

Publication Number Publication Date
HRP20180067T1 true HRP20180067T1 (hr) 2018-02-23

Family

ID=50931614

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20180067TT HRP20180067T1 (hr) 2012-12-19 2013-12-19 Inhibitori histon demetilaze

Country Status (17)

Country Link
US (4) US9617242B2 (enExample)
EP (1) EP2934145B1 (enExample)
JP (1) JP6256772B2 (enExample)
AU (1) AU2013361255B2 (enExample)
CA (1) CA2895355A1 (enExample)
CY (1) CY1119901T1 (enExample)
DK (1) DK2934145T3 (enExample)
ES (1) ES2658597T3 (enExample)
HR (1) HRP20180067T1 (enExample)
HU (1) HUE037312T2 (enExample)
LT (1) LT2934145T (enExample)
PL (1) PL2934145T3 (enExample)
PT (1) PT2934145T (enExample)
RS (1) RS56821B1 (enExample)
SI (1) SI2934145T1 (enExample)
SM (1) SMT201800070T1 (enExample)
WO (1) WO2014100463A1 (enExample)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3139033A1 (en) 2012-08-22 2014-02-27 Cornell University Methods for inhibiting fascin
ES2654143T3 (es) 2012-10-02 2018-02-12 Gilead Sciences, Inc. Inhibidores de desmetilasas de histonas
SI2934145T1 (en) 2012-12-19 2018-03-30 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
CA2895808A1 (en) 2012-12-21 2014-06-26 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
SG10201707027SA (en) 2013-02-27 2017-09-28 Epitherapeutics Aps Inhibitors of histone demethylases
JP6320506B2 (ja) 2013-03-12 2018-05-09 セルジーン クオンティセル リサーチ,インク. ヒストンデメチラーゼ阻害剤
RU2015143517A (ru) 2013-03-13 2017-04-19 Дженентек, Инк. Пиразолсодержащие соединения и их применения
WO2015127125A1 (en) 2014-02-20 2015-08-27 Cornell University Compounds and methods for inhibiting fascin
CN106660982B (zh) * 2014-06-25 2020-09-08 赛尔基因昆蒂赛尔研究公司 组蛋白脱甲基酶抑制剂
JP2017526675A (ja) 2014-08-27 2017-09-14 ギリアード サイエンシーズ, インコーポレイテッド ヒストンデメチラーゼを阻害するための化合物および方法
SG11201702119PA (en) 2014-09-17 2017-04-27 Quanticel Pharmaceuticals Inc Histone demethylase inhibitors
US10030017B2 (en) 2014-09-17 2018-07-24 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
SG11201702147TA (en) 2014-09-17 2017-04-27 Celgene Quanticel Res Inc Histone demethylase inhibitors
EP3397617A4 (en) 2015-12-28 2019-05-22 Celgene Quanticel Research, Inc. HISTONDEMETHYLASEINHIBITOREN
CN105601555B (zh) * 2016-03-14 2018-07-31 苏州大学 一种制备硝基吲哚衍生物的方法
WO2017161012A1 (en) * 2016-03-15 2017-09-21 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
ES2969239T3 (es) 2016-05-27 2024-05-17 Gilead Sciences Inc Combinación de ledipasvir y sofosbuvir para su uso en el tratamiento de infecciones por el virus de la hepatitis B en humanos
BR102017010009A2 (pt) 2016-05-27 2017-12-12 Gilead Sciences, Inc. Compounds for the treatment of hepatitis b virus infection
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
SI3507276T1 (sl) 2016-09-02 2022-01-31 Gilead Sciences, Inc. Spojine modulatorja toličnih receptorjev
WO2018045150A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
KR20230010826A (ko) 2016-10-14 2023-01-19 프리시젼 바이오사이언시스 인코포레이티드 B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제
EP3535242B1 (en) * 2016-10-20 2024-01-24 B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University Dna primase and gyrase inhibitors
TWI714820B (zh) 2017-01-31 2021-01-01 美商基利科學股份有限公司 替諾福韋艾拉酚胺(tenofovir alafenamide)之晶型
UY37581A (es) 2017-02-02 2018-08-31 Gilead Sciences Inc Compuestos para el tratamiento de la infección por virus de la hepatitis b
WO2018149986A1 (en) * 2017-02-16 2018-08-23 Oryzon Genomics, S.A. 2-(bicyclo-heteroaryl)-isonicotinic derivatives as histone demethylase inhibitors
ES2991090T3 (es) 2017-03-30 2024-12-02 Univ Freiburg Albert Ludwigs Inhibidores de KDM4
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
JP7037667B2 (ja) 2017-12-20 2022-03-16 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. Stingアダプタータンパク質を活性化するホスホン酸結合を有する3’3’環状ジヌクレオチド
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ, インコーポレイテッド Hbv複製阻害剤としての置換ピロリジン化合物
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 2,2,─環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
PE20210642A1 (es) 2018-07-13 2021-03-23 Gilead Sciences Inc Inhibidores de pd-1/pd-l1
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
EP4371987B9 (en) 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
EP3873608A1 (en) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
CN113574063B (zh) 2019-03-07 2025-03-18 捷克共和国有机化学与生物化学研究所 3’3’-环二核苷酸及其前药
WO2020178769A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
CN114245807B (zh) 2019-06-25 2025-05-02 吉利德科学公司 Flt3l-fc融合蛋白和使用方法
WO2021011891A1 (en) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
US20220296619A1 (en) 2019-08-19 2022-09-22 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
HRP20241379T1 (hr) 2019-09-30 2024-12-20 Gilead Sciences, Inc. Cjepiva za hbv i postupci za liječenje hbv
US12410418B2 (en) 2019-12-06 2025-09-09 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
KR102987126B1 (ko) 2020-03-20 2026-07-07 길리애드 사이언시즈, 인코포레이티드 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법
LT4192474T (lt) 2020-08-07 2025-11-25 Fosfonamidų nukleotidų analogų provaistai ir jų farmacinis panaudojimas
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
US20240269142A1 (en) 2021-05-13 2024-08-15 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
CN117355531A (zh) 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
JP7651018B2 (ja) 2021-06-23 2025-03-25 ギリアード サイエンシーズ, インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2024111560A1 (ja) 2022-11-21 2024-05-30 日本新薬株式会社 Ddr1キナーゼ阻害剤としての化合物および医薬
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
US20250345390A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
TW202608468A (zh) 2024-05-13 2026-03-01 美商基利科學股份有限公司 組合療法
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593349B2 (en) 2001-03-19 2003-07-15 Icagen, Inc. Bisarylamines as potassium channel openers
PL374946A1 (en) * 2002-09-05 2005-11-14 Aventis Pharma S.A. Novel aminoindazole derivatives as medicines and pharmaceutical compositions containing same
US7442698B2 (en) * 2003-07-24 2008-10-28 Amgen Inc. Substituted heterocyclic compounds and methods of use
FR2882361A1 (fr) * 2005-02-22 2006-08-25 Aventis Pharma Sa Nouveaux derives de 3-aryl-1,2-benzisoxazole, compositions les contenant et leur utilisation
DE602007004638D1 (de) * 2006-07-20 2010-03-18 Amgen Inc Benzoädüisoxazol-derivate als c-kit-tyrosinkinase-hemmer zur behandlung von erkrankungen im zusammenhang mit der überproduktion von histamin
EA018503B1 (ru) 2007-07-20 2013-08-30 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Замещенные производные индазола, активные как ингибиторы киназы
KR101361027B1 (ko) 2008-11-28 2014-02-11 코와 가부시키가이샤 피리딘-3-카르복시아미드 유도체
US8846935B2 (en) * 2010-05-07 2014-09-30 Glaxosmithkline Llc Indazoles
WO2012118812A2 (en) * 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
SI2934145T1 (en) 2012-12-19 2018-03-30 Celgene Quanticel Research, Inc. Histone demethylase inhibitors

Also Published As

Publication number Publication date
SMT201800070T1 (it) 2018-03-08
JP6256772B2 (ja) 2018-01-10
WO2014100463A1 (en) 2014-06-26
LT2934145T (lt) 2018-02-26
US10336727B2 (en) 2019-07-02
US20140171432A1 (en) 2014-06-19
US9617242B2 (en) 2017-04-11
EP2934145B1 (en) 2017-11-15
EP2934145A4 (en) 2016-06-29
HUE037312T2 (hu) 2018-08-28
US8969343B2 (en) 2015-03-03
PL2934145T3 (pl) 2018-04-30
ES2658597T3 (es) 2018-03-12
US20160060247A1 (en) 2016-03-03
CA2895355A1 (en) 2014-06-26
AU2013361255A1 (en) 2015-07-09
EP2934145A1 (en) 2015-10-28
AU2013361255B2 (en) 2017-01-05
US20180305336A1 (en) 2018-10-25
SI2934145T1 (en) 2018-03-30
US10040779B2 (en) 2018-08-07
DK2934145T3 (en) 2018-02-05
JP2016503799A (ja) 2016-02-08
CY1119901T1 (el) 2018-06-27
PT2934145T (pt) 2018-02-13
RS56821B1 (sr) 2018-04-30
US20170174656A1 (en) 2017-06-22

Similar Documents

Publication Publication Date Title
SI2934145T1 (en) Histone demethylase inhibitors
JP2016503799A5 (enExample)
JO3807B1 (ar) مشتقات حمض هيدروكسي جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
MX351581B (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen.
EA201791584A1 (ru) Агрохимическая композиция
EA201300200A1 (ru) N-((6-аминопиридин-3-ил)метил)гетероарилкарбоксамиды в качестве ингибиторов калликреина в плазме
CY1120480T1 (el) Ενωσεις πυραζολοπυριμιδινης
ES2626555T3 (es) Pyridone amides como moduladores de canales de sodio
BR112015022058A2 (pt) 7-azabiciclos substituídos e o uso destes como moduladores do receptor de orexina
PH12022552034A1 (en) Pyridone derivative having tetrahydropyranyl methyl group
EA201591301A1 (ru) Новые пиримидиновые и пиридиновые соединения и их применение
JO3263B1 (ar) مشتق إندان سلفاميد جديد
MY179290A (en) Post nerve injury rehabilitation effect-enhancing agent comprising alkyl ether derivative or salt thereof
CY1117688T1 (el) Ενωσεις τετραϋδροπυρρολοθειαζινης
UA117490C2 (uk) Сполуки ізоіндоліну або ізохіноліну, спосіб їх одержання і фармацевтичні композиції, що їх містять
EA201491276A1 (ru) Новые производные бензилсульфонамида, подходящие для применения в качестве ингибиторов mogat-2
PH12012502352A1 (en) Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
MX2016017371A (es) Sal de compuesto heterociclico sustituido con halogeno.
EA201590022A1 (ru) Новые производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные гетероциклами, в качестве противовирусных средств против респираторного синцитиального вируса
EA201600323A1 (ru) Производные пиперазина и их применение в качестве лекарственного средства
RU2016116036A (ru) Производное циклического амина и его фармацевтическое применение
CY1120101T1 (el) Παραγωγο πυριδονης και φαρμακο που το περιεχει
SI3083605T1 (en) COMPOUNDS OF FLUOROFENYL PIRAZOLE
EA201201668A1 (ru) Δ-кристаллическая форма аргининовой соли периндоприла, способ ее получения и содержащие ее фармацевтические композиции
MX350009B (es) Derivados de 2-metoxi-piridin-4-ilo.